Regenerative medicine company Juventas Therapeutics is touting the results from 12-month data of a phase 1 clinical trial of heart failure patients.
At 12 months, heart failure patients treated with the company’s stem cell therapy showed “significant” improvements in two key measures — a six-minute distance-walking test, as well as the Minnesota Living with Heart Failure Questionnaire, a patient self-assessment of how heart failure affects daily life.
Dr. Marc Penn, Juventas’ founder and chief medical officer, said the results of the trial suggest the company’s therapy is “inducing fundamental changes in the heart of treated patients,” according to a statement from Cleveland-based Juventas....
Read the complete story.